Noxopharm Limited (NOX:ASX)


right-arrow Created with Sketch. 0.035 (6.36%)
MCAP $151.0M
Last trade 16.10pm 22/01/2021 20mins delayed

Latest Announcements

09.10am 22/01/2021NOXNoxopharm Limited
09.09am 22/01/2021NOXNoxopharm Limited
08.26am 22/01/2021NOXNoxopharm Limited
13/01/2021 Price SensitivePSNOXNoxopharm Limited
12/01/2021NOXNoxopharm Limited
06/01/2021NOXNoxopharm Limited
23/12/2020NOXNoxopharm Limited
15/12/2020NOXNoxopharm Limited

Company Overview

Noxopharm Limited is a drug development company. The Company is engaged in the research and development of NOX66 in the field of adjuvant therapy in chemotherapy and radiotherapy. The Company focuses on developing a drug to treat cancer. The Company has a primary focus on the development of drugs to treat the problem of drug- and radio-resistance in cancer cells. The Company's drug NOX66 is a dosage formulation developed to protect idronoxil from being inactivated in the human body by Phase II metabolism. Its purpose is to ensure that idronoxil administered remains in an active form. The Company has its offices in Melbourne and Sydney.

NOX in the news

Search Previous Announcements